Jaunty Global Limited
-1.42%
3個月報酬率
$27.240
-1.367 (-5.02%)收盤時
Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG.
Kestra Medical Technologies is a good buy right now due to its significant revenue growth of 60% year-over-year, increasing from $19.37 million to $30.97 million, and a gross margin improvement to 56.5%, which is up over 10 percentage points year-over-year. The main risk is the widening net loss of $44.09 million for Q1 2027, which could impact investor sentiment.

CAIRDAC Appoints New Chairman of the Board

Kestra Medical Technologies Reports Q1 Financial Results with Revenue Growth

Kestra Medical Technologies Reports Strong Q1 Earnings with 60% Revenue Growth

Kestra Medical Technologies Appoints New VP of R&D

Kestra Appoints New VP of Research & Development
Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG. It operates in the Healthcare sector.
Kestra Medical Technologies is a good buy right now due to its significant revenue growth of 60% year-over-year, increasing from $19.37 million to $30.97 million, and a gross margin improvement to 56.5%, which is up over 10 percentage points year-over-year. The main risk is the widening net loss of $44.09 million for Q1 2027, which could impact investor sentiment.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。